See more : AIREA plc (AIEA.L) Income Statement Analysis – Financial Results
Complete financial analysis of Oncolytics Biotech Inc. (ONCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncolytics Biotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Türkiye Vakiflar Bankasi Türk Anonim Ortakligi (TKYVY) Income Statement Analysis – Financial Results
- Hyundai Motor Company (005385.KS) Income Statement Analysis – Financial Results
- Thruvision Group plc (DIGTF) Income Statement Analysis – Financial Results
- Guang Dong Sitong Group Co.,Ltd (603838.SS) Income Statement Analysis – Financial Results
- Schaffer Corporation Limited (SFC.AX) Income Statement Analysis – Financial Results
Oncolytics Biotech Inc. (ONCY)
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 783.46K | 699.76K | 313.31K | 208.87K | 0.00 | 310.00K | 1.00 |
| Cost of Revenue | 403.00K | 392.00K | 452.07K | 446.19K | 485.57K | 95.38K | 90.77K | 162.23K | 180.41K | 0.00 | 0.00 | 4.85M | 5.33M | 4.19M | 3.78M | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -403.00K | -392.00K | -452.07K | -446.19K | -485.57K | -95.38K | -90.77K | -162.23K | -180.41K | 0.00 | 0.00 | 0.00 | -5.33M | -4.19M | -3.78M | -4.31M | 0.00 | 0.00 | 783.46K | 699.76K | 313.31K | 208.87K | 0.00 | 310.00K | 1.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 17.71M | 15.43M | 12.92M | 12.94M | 11.13M | 9.42M | 9.39M | 9.77M | 8.60M | 13.82M | 18.51M | 31.40M | 23.39M | 12.19M | 12.15M | 13.35M | 11.32M | 10.54M | 9.31M | 7.11M | 3.31M | 4.28M | 5.12M | 3.69M | 486.66K |
| General & Administrative | 16.08M | 11.49M | 13.32M | 12.51M | 0.00 | 0.00 | 0.00 | 5.36M | 5.14M | 0.00 | 372.74K | 730.75K | 1.14M | 3.25M | 4.40M | 64.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -452.49K | -445.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.08M | 11.49M | 12.86M | 12.07M | 8.84M | 7.08M | 6.21M | 5.36M | 5.14M | 5.00M | 372.74K | 730.75K | 1.14M | 3.25M | 4.40M | 64.04K | 4.53M | 4.03M | 3.15M | 5.47M | 2.95M | 2.10M | 1.56M | 1.06M | 89.03K |
| Other Expenses | 0.00 | 0.00 | 13.31M | 12.51M | 9.56M | 7.24M | 6.21M | 162.23K | 180.41K | 5.00M | 5.02M | 4.55M | 0.00 | 409.84K | 425.40K | 341.97K | 5.53M | 4.96M | 4.00M | 6.22M | 3.62M | 2.68M | 2.02M | 1.27M | 90.71K |
| Operating Expenses | 33.79M | 26.92M | 26.23M | 25.46M | 20.69M | 16.66M | 15.61M | 15.29M | 13.92M | 18.82M | 23.90M | 36.69M | 28.72M | 15.51M | 17.00M | 13.76M | 16.85M | 15.50M | 13.31M | 13.33M | 6.93M | 6.96M | 7.14M | 4.96M | 577.37K |
| Cost & Expenses | 33.79M | 26.92M | 26.23M | 25.46M | 20.69M | 16.66M | 15.61M | 15.29M | 13.92M | 18.82M | 23.90M | 36.69M | 28.72M | 19.70M | 17.00M | 18.07M | 16.85M | 15.50M | 13.31M | 13.33M | 6.93M | 6.96M | 7.14M | 4.96M | 577.37K |
| Interest Income | 1.33M | 528.00K | 98.61K | 121.19K | 179.28K | 173.50K | 130.10K | 163.90K | 197.86K | 210.39K | 371.49K | 345.00K | 416.25K | 76.93K | 30.83K | 519.26K | 1.21M | 1.23M | 783.46K | 699.76K | 313.31K | 208.87K | 655.21K | 905.69K | 0.00 |
| Interest Expense | 0.00 | 528.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 81.00K | 392.00K | 452.07K | 446.19K | 485.57K | 95.38K | 90.77K | 162.23K | 180.41K | 163.50K | 131.62K | 109.28K | 92.59K | 63.16K | 257.25K | 410.25K | 1.00M | 926.68K | 855.99K | 751.76K | 663.52K | 574.24K | 465.45K | 205.20K | 1.68K |
| EBITDA | -33.71M | -26.83M | -25.66M | -25.37M | -20.02M | -17.18M | -15.51M | -15.13M | -13.74M | -18.66M | -23.77M | -36.58M | -27.93M | -19.29M | -16.75M | -17.66M | -15.83M | -14.53M | -12.46M | -12.58M | -5.95M | -6.18M | -6.67M | -4.44M | -575.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -753.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,457.86% | -1,651.52% | -1,296.66% | -2,957.46% | 0.00% | -1,432.41% | -57,569,100.00% |
| Operating Income | -33.79M | -28.57M | -26.23M | -25.46M | -20.69M | -16.66M | -15.61M | -15.29M | -13.92M | -18.82M | -23.90M | -36.69M | -28.72M | -20.04M | -17.00M | -18.07M | -16.85M | -15.50M | -12.53M | -12.63M | -6.62M | -6.75M | -7.14M | -4.65M | -577.37K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -756.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,599.39% | -1,805.23% | -2,112.40% | -3,232.38% | 0.00% | -1,498.60% | -57,737,000.00% |
| Total Other Income/Expenses | 6.14M | 2.17M | -20.06K | 2.95M | -12.43M | 173.50K | 130.10K | 163.90K | 197.86K | 210.39K | 371.49K | 345.00K | -283.43K | 76.93K | 30.83K | 519.26K | 1.20M | 1.20M | 529.09K | -323.88K | -1.89M | 0.00 | 655.21K | 905.69K | 0.00 |
| Income Before Tax | -27.66M | -24.75M | -26.25M | -22.51M | -33.12M | -16.49M | -15.48M | -15.13M | -13.72M | -18.61M | -23.53M | -36.34M | -29.00M | -19.97M | -16.97M | -17.55M | -15.64M | -14.30M | -12.78M | -12.96M | -8.51M | -6.75M | -6.48M | -3.74M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -749.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,631.66% | -1,851.52% | -2,716.36% | -3,232.38% | 0.00% | -1,206.44% | 0.00% |
| Income Tax Expense | 97.00K | 84.00K | 49.43K | -2.95M | 12.43M | 548.04K | 141.50K | 9.37K | 3.15K | 6.78K | 5.41K | 30.47K | 40.00K | 7.61K | 23.04K | 0.00 | -1.20M | -1.20M | -1.53K | 323.88K | 33.55K | -659.90K | -310.57K | -126.81K | -2.91K |
| Net Income | -27.75M | -24.84M | -26.30M | -19.55M | -45.55M | -17.04M | -15.62M | -15.14M | -13.72M | -18.62M | -23.53M | -36.37M | -29.04M | -19.97M | -17.00M | -17.55M | -15.64M | -14.30M | -12.78M | -12.96M | -8.54M | -6.09M | -6.17M | -3.61M | -574.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -749.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,631.47% | -1,851.52% | -2,727.07% | -2,916.44% | 0.00% | -1,165.53% | -57,446,200.00% |
| EPS | -0.41 | -0.43 | -0.49 | -0.48 | -2.06 | -1.06 | -1.12 | -1.20 | -1.16 | -2.01 | -2.68 | -4.54 | -3.89 | -3.04 | -3.27 | -4.03 | -3.68 | -3.74 | -3.71 | -4.31 | -3.48 | -2.74 | -3.17 | -2.09 | -0.93 |
| EPS Diluted | -0.41 | -0.43 | -0.49 | -0.48 | -2.06 | -1.06 | -1.12 | -1.20 | -1.16 | -2.01 | -2.68 | -4.54 | -3.89 | -3.04 | -3.27 | -4.03 | -3.68 | -3.74 | -3.71 | -4.31 | -3.48 | -2.74 | -3.17 | -1.98 | -0.93 |
| Weighted Avg Shares Out | 67.62M | 58.03M | 53.51M | 40.34M | 22.14M | 16.02M | 13.94M | 12.62M | 11.85M | 9.25M | 8.79M | 8.01M | 7.46M | 6.58M | 5.20M | 4.35M | 4.26M | 3.82M | 3.44M | 3.01M | 2.45M | 2.23M | 1.95M | 1.73M | 616.48K |
| Weighted Avg Shares Out (Dil) | 67.62M | 58.03M | 53.51M | 40.34M | 22.14M | 16.02M | 13.94M | 12.62M | 11.85M | 9.25M | 8.79M | 8.01M | 7.46M | 6.58M | 5.20M | 4.35M | 4.26M | 3.82M | 3.44M | 3.01M | 2.45M | 2.23M | 1.95M | 1.83M | 616.48K |
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pelareorep's ability to increase PD-L1 positive cells and T cell infiltration in the tumor microenvironment Data will support conduct of registrational program for pelareorep...
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic Cancer Action Network (PanCAN) provides financial boost and will enable further evaluation of pelareorep in pancreatic cancer Cash position...
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept SAN DIEGO and CALGARY, AB , Oct. 23, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY),(...
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Results met efficacy criteria for enrollment expansion and provide support for pelareorep's mechanism of action SAN DIEGO and CALGARY, AB , Oct. 23, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY), (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology,...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Oct. 20, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today...
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria SAN DIEGO and CALGARY, AB , Oct. 16, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC),...
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON and SAN DIEGO and CALGARY, AB , Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options...
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON, SAN DIEGO, and CALGARY, AB , Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people...
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference
SAN DIEGO and CALGARY, AB , Sept. 19, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced its participation in an analyst-led fireside chat at the Cantor Global Healthcare Conference 2023 with Chief...
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and CALGARY, AB , Sept. 6, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at the H.C.
Source: https://incomestatements.info
Category: Stock Reports